
INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.
INmune Bio Inc., founded as a clinical-stage biotechnology company, is dedicated to developing innovative treatments for cancer. With a mission to improve patient outcomes through targeted therapies, the company focuses on matching drug mechanisms to patient biology and employing relevant outcome metrics in clinical trials. INmune Bio's core products and services revolve around immuno-oncology, aiming to harness the body's immune system to combat cancer effectively. Their market focus is primarily within the United States, serving patients and healthcare providers seeking advanced cancer treatment options.
Notable individuals affiliated with INmune Bio include leading scientists and industry experts in immuno-oncology. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements include the progression of multiple drug candidates through various stages of clinical trials, demonstrating promising efficacy and safety profiles. INmune Bio's impact is marked by its commitment to pioneering cancer therapies that offer new hope for patients, potentially transforming the landscape of cancer treatment.

Immunome

ImmunityBio
immunitybio.com

Inimmune
inimmune.com

Immune-Onc Therapeutics
immuneonc.com

ImmunoGenesis
immunogenesis.com

Nantkwest

Imunon
imunon.com

Imvaq Therapeutics

Iovance Biotherapeutics
iovance.com

NextCure
nextcure.com

ImmunoMet Therapeutics
immunomet.com

Immuneering
immuneering.com

Cancervax
cancervax.com

Immunitas Therapeutics
immunitastx.com

Imvax
imvax.com
Companies similar to INmune Bio include Immunome, ImmunityBio, Inimmune and Immune-Onc Therapeutics.
INmune Bio was founded in 2015.
INmune Bio's headquarters is located in Boca Raton, FL, US.
INmune Bio's most recent funding round was for $40M (USD) in July 2021.
As of Jul 14, 2021, INmune Bio has raised a total of $103.2M (USD).
INmune Bio has 17 employees as of Feb 6, 2024.